Gritstone bio Inc (OQ:GRTS)

Apr 16, 2024 12:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
Pomerantz LLP is investigating claims on behalf of investors of  Gritstone bio, Inc.  (“Gritstone” or the “Company”) (NASDAQ: GRTS).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Apr 15, 2024 07:00 am ET
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Publication underscores the important role of antigen selection and cassette design in the development of neoantigen-directed immunotherapy -- EMERYVILLE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a...
Apr 12, 2024 09:30 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
NEW YORK, April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Gritstone bio, Inc.  ("Gritstone" or the "Company") (NASDAQ: GRTS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Apr 08, 2024 02:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
Pomerantz LLP is investigating claims on behalf of investors of  Gritstone bio, Inc.  (“Gritstone” or the “Company”) (NASDAQ: GRTS).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Apr 08, 2024 08:00 am ET
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences. Select...
Apr 08, 2024 07:00 am ET
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today...
Apr 04, 2024 07:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
NEW YORK, April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Apr 01, 2024 11:00 pm ET
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or...
Apr 01, 2024 04:10 pm ET
Gritstone bio Announces Proposed Public Offering
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded...
Apr 01, 2024 04:01 pm ET
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vacci
Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control)...
Mar 23, 2024 04:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Mar 15, 2024 10:31 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Mar 08, 2024 07:30 am ET
Did Gritstone bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate – GRTS
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws.
Mar 07, 2024 07:25 am ET
Levi & Korsinsky Announces an Investigation on Behalf of Gritstone bio, Inc. (GRTS) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws.
Mar 05, 2024 04:15 pm ET
GRTS ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Gritstone bio, Inc.
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws.
Mar 05, 2024 04:05 pm ET
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent...
Feb 29, 2024 04:05 pm ET
Gritstone bio Announces Workforce Reduction 
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% reduction of its workforce. The move comes following the recently announced delay...
Feb 21, 2024 07:00 am ET
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences: 2024 BIO...
Feb 12, 2024 07:00 am ET
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it is now preparing to launch the Phase 2b head-to-head trial of its next-generation COVID-19...
Feb 08, 2024 04:30 pm ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted six employees nonqualified...
Jan 17, 2024 07:00 am ET
Gritstone bio to Participate in Upcoming Investor Conference
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conference: B. Riley Securities' 4th...
Jan 10, 2024 04:30 pm ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified...
Dec 07, 2023 04:30 pm ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted four employees...
Nov 20, 2023 07:00 am ET
Gritstone bio to Participate in Upcoming Investor Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: 6th Annual Evercore ISI...
Nov 08, 2023 04:05 pm ET
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
run Phase 1 study evaluating an autologous T cell therapy in combination with Gritstone’s “off-the-shelf" cancer vaccine, SLATE-KRAS -- -- Cash, cash equivalents, marketable securities and restricted cash of $90.5 million as of September 30, 2023...
Nov 07, 2023 04:30 pm ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified...
Oct 12, 2023 05:00 pm ET
Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced the use of its LNP technology in Gritstone bio’s (Nasdaq: GRTS)...
Oct 11, 2023 07:10 am ET
Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
October 11, 2023 (GLOBE NEWSWIRE) – Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the presentation of results from three ongoing Phase 1 studies...
Oct 10, 2023 07:00 am ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted three employees...
Oct 04, 2023 04:05 pm ET
Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced results from all three (3) Phase 1 studies evaluating its self-amplifying mRNA (samRNA) vaccine...
Sep 27, 2023 04:01 pm ET
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to...
Sep 13, 2023 04:30 pm ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified...
Sep 05, 2023 07:00 am ET
Gritstone bio to Participate in Upcoming Investor Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: 2023 Wells Fargo...
Aug 16, 2023 04:30 pm ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified...
Aug 15, 2023 07:00 am ET
Gritstone bio and Genevant Sciences Announce Option and License Agreement
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive...
Aug 09, 2023 04:05 pm ET
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical...
Aug 07, 2023 07:00 am ET
Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company has joined the ctMoniTR Project, a collaborative research initiative providing...
Jul 17, 2023 07:00 am ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted four employees...
Jun 08, 2023 07:00 am ET
Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications
-- Data underscore the potential of Gritstone’s samRNA candidates to serve as next-generation vaccines against COVID-19 and other infectious diseases -- EMERYVILLE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a...
Jun 01, 2023 04:30 pm ET
Gritstone bio to Participate in Upcoming Investor Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: Goldman Sachs 44th Annual...
May 24, 2023 05:00 pm ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified...
May 11, 2023 04:05 pm ET
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate and clinical...
May 03, 2023 07:00 am ET
Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market...
Apr 17, 2023 07:01 am ET
Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
-- Data further support the favorable tolerability and distinctive immunogenicity profile of self-amplifying mRNA (samRNA) -- EMERYVILLE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage...
Apr 17, 2023 07:00 am ET
Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, is delivering three presentations related to the company’s neoantigen vaccine programs and capabilities at the 2023...
Apr 10, 2023 07:00 am ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified...
Apr 04, 2023 06:30 pm ET
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases...
Mar 15, 2023 07:00 am ET
Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting,...
Mar 09, 2023 04:05 pm ET
Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent...
Mar 02, 2023 07:00 am ET
Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report its fourth quarter and full year 2022 financial results and provide a corporate update...
Feb 27, 2023 04:06 pm ET
Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Gritstone’s Co-founder, President and Chief Executive Officer will...
Feb 27, 2023 04:05 pm ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted three employees...
Feb 14, 2023 07:00 am ET
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an...
Jan 24, 2023 07:00 am ET
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted two employees nonqualified stock options to purchase an...
Jan 18, 2023 05:30 pm ET
Gritstone bio to Participate in Upcoming Investor Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will participate in the following investor conferences. B. Riley Securities' 3rd Annual...
Dec 15, 2022 04:31 pm ET
Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will present at the...
Dec 15, 2022 04:30 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted five employees nonqualified stock options to purchase an...
Dec 13, 2022 07:00 am ET
Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that the United States Patent and Trademark Office (USPTO) recently issued two new patents related to...
Dec 05, 2022 08:30 am ET
Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors
Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company’s strategic initiatives and commercialization efforts....
Nov 21, 2022 07:30 am ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted nine employees nonqualified stock options to purchase an...
Nov 17, 2022 07:00 am ET
Gritstone to Participate in Upcoming Investor Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor conferences. 5th Annual...
Nov 10, 2022 09:00 am ET
Gritstone Announces Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced updated overall survival (OS) results from its Phase 1/2 study evaluating GRANITE, an individualized...
Nov 03, 2022 04:05 pm ET
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
-- GRANITE randomized Phase 2/3 study in 1L metastatic CRC with registrational intent ongoing; preliminary Phase 2 data expected in 4Q2023 -- -- Cash, cash equivalents, marketable securities and restricted cash of $151.8 million as of September...
Oct 25, 2022 07:01 am ET
Gritstone bio Announces Private Placement of $45.0 Million
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that it has executed a securities purchase agreement to sell, through a private investment in public...
Oct 25, 2022 07:00 am ET
Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced positive Phase 1 results from its ongoing CORAL-BOOST and CORAL-CEPI trials evaluating its...
Oct 19, 2022 07:00 am ET
Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that it will host a webinar on October 25, 2022 to present data from its CORAL program and discuss the...
Oct 17, 2022 07:00 am ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted seven employees nonqualified stock options to purchase...
Sep 20, 2022 07:00 am ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted three employees nonqualified stock options to purchase...
Sep 12, 2022 07:00 am ET
Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022
-- Molecular response, as measured by reduction in circulating tumor DNA (ctDNA) from baseline, demonstrates a correlation with overall survival (OS) in NSCLC, consistent with industry literature -- -- SLATE-KRAS vaccine candidate elicits robust...
Sep 01, 2022 04:05 pm ET
Gritstone to Participate in Two Upcoming Investor Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that management will present at the 2022 Wells Fargo Healthcare Conference, taking place September...
Aug 17, 2022 07:00 am ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted eight employees nonqualified stock options to purchase...
Aug 15, 2022 04:05 pm ET
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based...
Aug 10, 2022 04:05 pm ET
Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced the appointment of Lawrence “Larry” Corey, M.D., to its Board of Directors. An internationally...
Aug 04, 2022 04:05 pm ET
Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update
-- New credit facility provides financial flexibility entering period of multiple potential milestones -- -- Cash, cash equivalents, marketable securities and restricted cash of $159.2 million as of June 30, 2022 -- -- Gritstone will host a...
Jul 26, 2022 07:00 am ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors has granted three employees nonqualified stock options to...
Jul 21, 2022 04:06 pm ET
Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that it will host a conference call and webcast at 4:30pm ET on Thursday, August 4, 2022, to report its second...
Jul 21, 2022 04:05 pm ET
Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and Silicon Valley Bank
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced it has entered into an $80 million credit facility with Hercules Capital, Inc. (NYSE: HTGC) and...
Jul 05, 2022 08:00 am ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors has granted eight employees nonqualified stock options to...
Jun 10, 2022 08:00 am ET
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced results from a preclinical study evaluating a self-amplifying mRNA (samRNA) vaccine candidate against...
Jun 08, 2022 04:05 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors has granted eighteen employees nonqualified stock options to...
Jun 02, 2022 08:00 am ET
Gritstone Earns 2022 Great Place to Work Certification™
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company has been certified as a Great Place to Work by the Great Place to Work® Institute....
May 31, 2022 08:00 am ET
Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced updated overall survival (OS) results from its Phase 1/2 study evaluating GRANITE, an individualized...
May 17, 2022 05:00 pm ET
Gritstone to Participate in H.C. Wainwright Global Investment Conference
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone, will...
May 06, 2022 07:30 pm ET
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
In a release issued under the same headline on May 5, 2022 by Gritstone bio, Inc. (Nasdaq: GRTS), please note that two values in the Condensed Consolidated Statements of Operations table and one value in the Condensed Consolidated Balance Sheets...
May 05, 2022 04:05 pm ET
Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2022 and reviewed business highlights....
May 02, 2022 07:00 am ET
Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it will report its financial results for the first quarter ended March...
Apr 27, 2022 04:05 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted nine employees...
Apr 12, 2022 04:35 pm ET
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
-- GRANITE data (individualized neoantigen-based therapeutic vaccine program) support circulating tumor DNA (ctDNA) response as a predictor of overall survival in metastatic colorectal cancer -- -- Detailed analysis from oncology programs...
Mar 30, 2022 07:00 am ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted five employees...
Mar 10, 2022 04:05 pm ET
Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today reported financial results for the fourth quarter and full year ended December 31,...
Mar 08, 2022 05:15 pm ET
Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced three abstracts have been accepted for presentation at the upcoming American...
Feb 24, 2022 07:00 am ET
Gritstone to Participate in Cowen 42nd Annual Health Care Conference
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive...
Feb 08, 2022 04:05 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted five employees...
Feb 08, 2022 07:00 am ET
Gritstone to Participate in Precision Oncology Panel at BIO CEO & Investor Conference
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive...
Jan 25, 2022 04:05 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted eleven employees...
Jan 13, 2022 07:00 am ET
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Color
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the first patient has been enrolled for inclusion in the Phase 2/3...
Jan 04, 2022 07:00 am ET
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today shared positive Phase 1 clinical data from the first cohort (10 µg dose of CORAL...
Dec 30, 2021 07:00 am ET
Gritstone Announces Presentations during Three Upcoming Investor Conferences
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in the following upcoming...
Dec 17, 2021 07:00 am ET
Gritstone Announces Changes to Its Board of Directors
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced changes to its Board of Directors. Clare Fisher, a talented corporate and...
Dec 13, 2021 04:05 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted eight employees...
Dec 13, 2021 07:00 am ET
Gritstone bio Added to the Nasdaq Biotechnology Index
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI),...
Dec 09, 2021 07:41 am ET
Direxion Launches mRNA ETF (MSGR)
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology.
Dec 06, 2021 07:00 am ET
Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of...
Nov 29, 2021 07:00 am ET
The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying...
Nov 23, 2021 04:05 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted fourteen employees...
Nov 10, 2021 07:00 am ET
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today published positive preclinical data in non-human primate models from the CORAL...
Nov 03, 2021 04:05 pm ET
Gritstone Reports Third Quarter 2021 Financial Results and Business Update
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the third quarter ended September 30, 2021 and reviewed...
Oct 25, 2021 04:01 pm ET
Gritstone Announces Presentations during Five Upcoming Investor Conferences and Events
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in five upcoming investor...
Sep 24, 2021 04:05 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the company’s Board of Directors has...
Sep 20, 2021 07:01 am ET
Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the first volunteer has been dosed in a Phase 1 trial evaluating the ability...
Sep 17, 2021 09:31 am ET
Thinking about buying stock in Innate Pharma, Beachbody Company, Gritstone bio, Enveric Biosciences, or Lucid Group?
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IPHA, BODY, GRTS, ENVB, and LCID.
Sep 17, 2021 07:02 am ET
Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced results with its SLATE v1 product (“off-the-shelf" shared neoantigen immunotherapy...
Sep 17, 2021 07:01 am ET
Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Reg
GRANITE individualized immunotherapy demonstrates objective evidence of efficacy in end-stage colorectal cancer (CRC) patients (3rd line or greater) who have “cold” tumors at baseline 44% molecular response rate (4/9) by ctDNA (circulating tumor...
Sep 16, 2021 04:01 pm ET
Gritstone Announces Private Placement Financing of $55.0 Million
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies and vaccines, today announced a $55.0 million private investment in public equity (PIPE) financing...
Sep 09, 2021 04:05 pm ET
Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it will host a data update webcast for investors and analysts during...
Sep 07, 2021 04:00 pm ET
Gritstone Announces Presentations at Two Investor Conferences in September
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will present webcasted company overviews at two...
Aug 17, 2021 07:00 am ET
Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the company entered into a funding agreement of up to $20.6 million with the...
Aug 16, 2021 04:00 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the company’s Board of Directors has...
Aug 11, 2021 07:00 am ET
Gritstone to Host Key Opinion Leader Webinar on its Neoantigen Oncology Programs
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that it will host a key opinion leader (KOL) webinar on its neoantigen oncology...
Aug 05, 2021 04:00 pm ET
Gritstone Reports Second Quarter 2021 Financial Results and Business Update
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the second quarter ended June 30, 2021 and reviewed business...
Jul 15, 2021 04:00 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the company’s Board of Directors has...
Jun 23, 2021 08:00 am ET
Gritstone Announces Management Changes, Including the Appointment of Celia Economides as Chief Financial Officer
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced the appointment of Celia Economides as executive vice president and chief financial...
Jun 17, 2021 08:00 am ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the company’s Board of Directors has...
Jun 07, 2021 08:00 am ET
Gritstone to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer,...
Jun 01, 2021 08:00 am ET
Gritstone Announces Changes to Its Board of Directors
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced changes to its Board of Directors. Naiyer A. Rizvi, M.D., newly appointed chief...
May 24, 2021 04:00 pm ET
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the company’s Board of Directors has...
May 06, 2021 09:01 am ET
Gritstone Reports First Quarter 2021 Financial Results and Business Highlights
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the first quarter ended March 31, 2021 and reviewed business...
May 03, 2021 08:00 am ET
Gritstone Oncology Changes its Name to Gritstone bio to Reflect Expanded Therapeutic Focus
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced it is changing its name to Gritstone bio, Inc. effective immediately....
Mar 29, 2021 07:00 am ET
Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the first person has been dosed under Gritstone’s “CORAL” program...
Mar 11, 2021 09:01 am ET
Gritstone Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2020...
Mar 08, 2021 08:00 am ET
Gritstone Announces Promotions Within its Leadership Team
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced two promotions within its leadership team. Karin Jooss, Ph.D.,...
Mar 02, 2021 08:00 am ET
Gritstone to Present at the H.C. Wainwright Global Life Sciences Conference
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive...
Feb 01, 2021 06:00 am ET
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection.
Jan 20, 2021 08:00 am ET
Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and Genevant Sciences, a leading nucleic acid delivery company with world-class...
Jan 19, 2021 06:00 am ET
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it is advancing development of a second generation vaccine against...
Jan 11, 2021 08:00 am ET
Gritstone Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Jan 05, 2021 07:30 am ET
Thinking about buying stock in Aileron Therapeutics, Check Cap, Jaguar Health, Clearside Biomedical, or Gritstone Oncology?
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALRN, CHEK, JAGX, CLSD, and GRTS.
Dec 28, 2020 08:00 am ET
Gritstone Oncology Announces Private Placement Financings Totaling $125 Million
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the closing of the previously announced $110 million private...
Dec 23, 2020 08:33 am ET
Gritstone Oncology Announces $110 Million Private Placement
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has executed a securities purchase agreement to raise...
Nov 05, 2020 09:01 am ET
Gritstone Oncology Reports Third Quarter Financial Results and Recent Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the third quarter ended September 30, 2020...
Nov 02, 2020 08:00 am ET
Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has begun dosing patients in the Phase 2 expansion...
Sep 15, 2020 08:00 am ET
Gritstone Oncology Announces Updated Presentation Time at Cantor Virtual Global Healthcare Conference
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Sep 08, 2020 08:00 am ET
Gritstone Oncology to Webcast Presentations from Two Upcoming Investor Conferences in September
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Aug 05, 2020 09:01 am ET
Gritstone Oncology Reports Second Quarter Financial Results and Recent Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the second quarter ended June 30, 2020 and...
Aug 03, 2020 08:00 am ET
Gritstone Oncology to Present at Two Upcoming Investor Conferences in August
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced presentations at two upcoming investor conferences in August. Karin...
Jun 24, 2020 08:00 am ET
Gritstone Oncology to Present Clinical Data from Ongoing GRANITE and SLATE Phase 1 Studies During Investor Webcast on July 13
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the Gritstone management team will host an investor...
Jun 10, 2020 08:00 am ET
Gritstone Oncology Announces the Addition of Jean-Charles Soria, M.D., Ph.D., to its Scientific Advisory Board
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Charles Soria, M.D., Ph.D., chief executive officer...
Jun 04, 2020 08:00 am ET
Gritstone Oncology to Present at Two Upcoming Investor Conferences in June
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
May 07, 2020 09:01 am ET
Gritstone Oncology Reports First Quarter Financial Results and Recent Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the first quarter ended March 31, 2020 and...
May 01, 2020 08:00 am ET
Gritstone Oncology Announces the Appointment of Dr. Elaine V. Jones as Chair of the Board of Directors
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the appointment of Elaine V. Jones, Ph.D., as chair of the...
Apr 06, 2020 08:00 am ET
Gritstone Oncology Announces the Appointment of Veteran Legal Executive Rahsaan Thompson as General Counsel
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the appointment of Rahsaan W. Thompson as its executive vice...
Mar 11, 2020 09:01 am ET
Gritstone Oncology Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the fourth quarter and full year ended...
Feb 25, 2020 04:00 pm ET
Gritstone Oncology to Present at Two Investor Conferences in March
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Jan 08, 2020 04:00 pm ET
Gritstone Oncology to Present at the 38th Annual J.P. Morgan Healthcare Conference
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Dec 12, 2019 05:05 am ET
Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the company has presented preliminary Phase 1 GRANITE...
Dec 09, 2019 08:00 am ET
Gritstone Oncology to Webcast a Review of the Clinical Immunogenicity Data from its Neoantigen-based Immunotherapies that will be Presented at the ESMO Immuno-Oncology Congress
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the executive management team will webcast a review of...
Nov 26, 2019 08:00 am ET
Gritstone Oncology to Present at the Piper Jaffray Annual Healthcare Conference
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Nov 12, 2019 09:01 am ET
Gritstone Oncology Reports Third Quarter 2019 Financial Results and Recent Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported recent business highlights and financial results for the third...
Nov 05, 2019 08:05 am ET
Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE Platform and Contained Within its SLATE Immunotherapy
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced data on novel shared tumor-specific neoantigens (TSNA) arising...
Oct 31, 2019 08:00 am ET
Gritstone Oncology to Webcast Investor Event Reviewing its Neoantigen-based Immunotherapies During SITC Conference
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it will webcast an investor event with its executive management...
Oct 07, 2019 08:00 am ET
Gritstone Oncology Announces Upcoming Presentation on Novel Shared Neoantigens Included within “Off-The-Shelf” SLATE Immunotherapy at SITC 2019 Annual Meeting
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it will present the novel shared neoantigens included...
Sep 26, 2019 08:00 am ET
Gritstone Oncology to Present at Cantor Global Healthcare Conference
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Marc Bellemin, M.B.A., executive vice president and chief...
Sep 12, 2019 08:00 am ET
Gritstone Oncology Announces Changes to its Board of Directors, Including the Appointment of Biotech Veteran Dr. Elaine V. Jones
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced changes to its board of directors. Elaine V. Jones, Ph.D., has...
Aug 14, 2019 08:00 am ET
Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of immunotherapies to fight multiple cancer types, today announced that the first SLATE patient has been dosed. SLATE is an...
Aug 12, 2019 09:01 am ET
Gritstone Oncology Reports Second Quarter 2019 Financial Results and Recent Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported recent business highlights and financial results for the second...
Jul 08, 2019 08:00 am ET
Gritstone Oncology Announces the Appointment of Dr. Vijay Yabannavar, a Biopharma Leader with Over 30 Years of Experience, as Executive Vice President of Manufacturing and Technical Operations
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Vijay Yabannavar, Ph.D., has joined the company as...
Jun 05, 2019 08:00 am ET
Gritstone Oncology to Present at Two Upcoming Investor Conferences in June
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
May 30, 2019 08:00 am ET
Gritstone Oncology to Host Event with Oncology Key Opinion Leaders Discussing Neoantigen-based Immunotherapy During ASCO Annual Meeting
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it will webcast an event with key opinion leaders who will...
May 13, 2019 09:01 am ET
Gritstone Oncology Reports First Quarter 2019 Financial Results and Recent Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported recent business highlights and financial results for the first...
Apr 24, 2019 08:53 pm ET
Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock
Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing of its underwritten public offering of 6,500,000 shares of common stock at a public offering price of $11.50 per share, before underwriting discounts and commissions. All of the...
Apr 22, 2019 04:28 pm ET
Gritstone Oncology Announces Proposed Public Offering of Common Stock
Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced that it has commenced an underwritten public offering of 6,500,000 shares of common stock. All of the shares of common stock are being offered by Gritstone Oncology. In addition, Gritstone...
Apr 22, 2019 08:00 am ET
Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback
Gritstone Oncology, Inc. (Nasdaq: GRTS), an immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types, today announced that following feedback from the U.S. Food and Drug Administration (FDA) the SLATE...
Apr 04, 2019 08:00 am ET
Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Eugene Zhukovsky, Ph.D., an expert in the development of...
Apr 03, 2019 04:00 pm ET
Gritstone Oncology to Present at Needham Healthcare Conference
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Apr 02, 2019 04:00 pm ET
Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE™ Significantly Outperforms Current Prediction Methods
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the presentation of data demonstrating its ability to identify...
Mar 28, 2019 04:00 pm ET
Gritstone Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the fourth quarter and full year ended...
Mar 21, 2019 04:00 pm ET
Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the first patient has been dosed with its personalized...
Mar 11, 2019 08:00 am ET
Gritstone Oncology Announces the Appointment of Technology Executive, Mike Forcht, as Senior Vice President of Human Resources to Support Vision for Growth
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Mike Forcht, Ed.D., M.B.A., has joined the company as...
Mar 05, 2019 04:00 pm ET
Gritstone Oncology to Present at Two Upcoming Investor Conferences in March
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Feb 27, 2019 06:12 pm ET
Gritstone Oncology Announces Oral Presentation on MHC Class II Antigen Prediction at the AACR Annual Meeting in April 2019
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced two abstracts have been accepted for presentation at the...
Feb 20, 2019 04:00 pm ET
Gritstone Oncology to Present at Leerink Partners Annual Global Healthcare Conference
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Marc Bellemin, M.B.A., executive vice president and chief...
Jan 06, 2019 08:00 am ET
Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Jan 03, 2019 06:16 pm ET
Gritstone Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief...
Dec 20, 2018 04:00 pm ET
Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Dec 19, 2018 03:17 pm ET
TCR2 Therapeutics Announces Oncology Industry Leader and Expert Andrew Allen, M.D., Ph.D. Joins its Board of Directors
CAMBRIDGE, Mass., Dec. 19, 2018 /PRNewswire/ -- TCR2 Therapeutics Inc., an innovative immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced the appointment of Andrew Allen, M.D., Ph.D. to its Board of Directors. An industry leader with expertise in cancer clinical development, Dr. Allen co-founded Gritstone Oncology, Inc., (NASDAQ: GRTS) in 2015, and currently serves as Gritstone's President and Chief Executive Officer (CEO) and member of its Board of Directors.
Dec 17, 2018 11:00 am ET
Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE™
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that data demonstrating the predictive performance of its...
Dec 10, 2018 07:00 am ET
Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it is advancing its bispecific antibody (BiSAb) program...
Nov 14, 2018 08:00 am ET
Gritstone Oncology Reports Third Quarter 2018 Financial Results and Recent Business Highlights
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported recent business highlights and financial results for the third...
Sep 27, 2018 09:30 pm ET
Gritstone Oncology Announces Pricing of Initial Public Offering
Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.